期刊文献+

尼达尼布有关物质测定方法的建立 被引量:1

Establishment of Determination Method for the Related Substances in Nintedanib
原文传递
导出
摘要 目的:建立尼达尼布的有关物质测定方法,并进行方法学验证。方法:采用XBridge RP-C_(18)色谱柱(250 mm×4.6 mm,3.5μm),以甲醇-0.1%三氟乙酸为流动相进行梯度洗脱,流速为1.0 ml·min^(-1),检测波长为287 nm,柱温为35℃,进样量为10ul。结果:主成分与各杂质峰分离度良好,杂质1~4分别在0.103 0~1.030 4μg·ml^(-1)(r=0.999 5),0.202 9~1.014 5μg·ml^(-1)(r=0.999 7),0.199 9~0.999 6μg·ml^(-1)(r=0.999 9),0.200 6~1.002 9μg·ml^(-1)(r=0.998 4)范围内线性关系良好,检测限分别为0.31,0.61,0.60,0.60 ng;平均回收率分别为98.3%、99.3%、97.9%、99.8%,RSD分别为2.1%、2.1%、3.0%、1.1%。结论:该方法简便,准确,灵敏度高,专属性强,适用于本品有关物质的测定。 Objective: To establish and verify an HPLC method for determining the related substances in nintedanib. Methods: An XBridge RP-Cls (250 mm x4.6 Into,3.5 pLm) column was used, and the column temperature was set at 35~C. The mobile phase was composed of methanol and 0.1% trifluoroaeetic acid with gradient elution. The flow rate was 1.0 ml·min^-1. The detection wavelength was 287 nm. The injection volume was 10μl. Results: Nintedanib and its related substances could be well separated, and impurity 1-4 showed a good linear relationship within the range of 0. 103 0-1. 030 4μg·ml^-1( r = 0. 999 5 ) ,0.202 9-1. 014 5μg·ml^-1( r = 0.999 7 ), 0. 199 9-0.999 6μg·ml^-1( r = 0.999 9 ) and 0.200 6-1. 002 9μg·ml^-1( r = 0.998 4 ), respectively. The detection limit was 0.31, 0.61, 0.60, 0.60 ng, the average recovery was 98.3%, 99.3%, 97.9% and 99.8%, and RSD was 2.1%, 2.1%, 3.0% and 1.1%, respectively. Conclusion: The method is simple and accurate with high sensitivity and strong specificity, which is suitable for the determination of the relatedsubstances in nintedanib.
出处 《中国药师》 CAS 2016年第11期2188-2192,共5页 China Pharmacist
关键词 尼达尼布 有关物质 高效液相色谱法 Nintedanib Related substances HPLC
  • 相关文献

参考文献2

二级参考文献17

  • 1Hilberg F, Roth GJ, Merger M, et al. BIBF 1120 angiogenesis inhibitor oncolytic[J]. Drugs Future, 2010, 35 (1) : 5-10.
  • 2Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [J]. Cancer Res, 2008, 68 (12) : 4774-4782.
  • 3Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis [J]. N Engl J Med, 2011,365 (12) : 1079-1087.
  • 4Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl- substituted indolinone (BIBF 1120)[J]. J Med Chem, 2009,52 (14) : 4466-4480.
  • 5Roth GJ, Heekel A, Walter R, et al. Substituted indolines which inhibit receptor tyrosine kinases. US, 6762180 [P]. 2004-07-13. (CA2004, 134: 311105).
  • 6Gilman NW, Levitan P, Sternbach LH. An extension of the smiles rearrangement. The displacement of an aromatic amide group by an amine nitrogen [J]. J Org Chem, 1973, 38(2): 373-377.
  • 7Roth GJ, Heckel A, Lehmann-Lintz T, et al. Preparation of indolinone-6-carboxylic acids as inhibitors of endothelial cell proliferation. DE, 10117204 [P]. 2002-10-10. (CA 2002, 137: 279089).
  • 8Adhikary KK, Lee HW. Nucleophilic substitution reactions of N-methyl bromoacetanilides with benzylamines in dimethyl sulfoxide [J]. Bull Korean Chem Soc, 2011, 32 (3): 857-862.
  • 9Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [ J]. Cancer Res, 2008 ;68:4774-4782.
  • 10Antoniu SA, Kolb MR. Nintedanib, a triple kinase inhibitor of VEG- FR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis[ J ]. IDrugs ,2010 ; 13:332-345.

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部